A longitudinal study of anti-SARS-CoV-2 antibody seroprevalence in a random sample of the general population in Hiroshima in 2020.
Sugiyama A, Okada F, Abe K, Imada H, Ouoba S, E B, Hussain MRA, Ohisa M, Ko K, Nagashima S, Akita T, Yamazaki S, Yokozaki M, Kishita E, Tanaka J.
Sugiyama A, et al. Among authors: tanaka j.
Environ Health Prev Med. 2022;27:30. doi: 10.1265/ehpm.22-00016.
Environ Health Prev Med. 2022.
PMID: 35793938
Free PMC article.